Combining immunotherapy with capivasertib for advanced bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding a new targeted drug, capivasertib, to standard immunotherapy (immune checkpoint inhibitors) can help people with advanced bladder cancer whose disease has stabilized or progressed after at least 12 weeks of immunotherapy. The goal is to see if this combination slows cancer growth and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or recurrent bladder cancer (urothelial carcinoma) that is stage III or IV.
- You have had at least 12 weeks of an immunotherapy drug (like pembrolizumab) and your cancer has either stayed the same or grown.
- You have had a prior treatment called enfortumab vedotin (unless you could not take it).
- You have had genomic testing that includes checking for changes in genes like PIK3CA, AKT1, or PTEN.
- You feel generally well (minimal symptoms) and can manage daily activities.
- You have measurable disease by scans (at least one tumor that can be measured on CT or MRI).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
This trial tests a new combination of two drugs (rimegepant and toripalimab) for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if this combination can help shrink or control the cancer.
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
Hear when a new Advanced Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.